Page last updated: 2024-10-29

isocarboxazid and Huntington Disease

isocarboxazid has been researched along with Huntington Disease in 1 studies

Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research Excerpts

ExcerptRelevanceReference
"Depression is common in Huntington's disease."1.27Treatment of depression in Huntington's disease with monoamine oxidase inhibitors. ( Ford, MF, 1986)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ford, MF1

Other Studies

1 other study available for isocarboxazid and Huntington Disease

ArticleYear
Treatment of depression in Huntington's disease with monoamine oxidase inhibitors.
    The British journal of psychiatry : the journal of mental science, 1986, Volume: 149

    Topics: Adult; Aged; Depression; Female; Humans; Huntington Disease; Isocarboxazid; Middle Aged; Monoamine O

1986